ALFA Filings
Every announcement, straight from the exchange
Every Supriya Lifescience earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements with these filters
Supriya Lifescience is pivoting to Finished Dosage Forms (FDF) and R&D-driven specialized therapies with a new dedicated manufacturing unit. Focus is on high-margin Anaesthetic, Anti-diabetic, and CNS portfolios.
Supriya Lifescience reported Q1 FY27 revenue of INR 1,897.5 Mn, up 31% YoY, despite EBITDA and PAT compression. The company is pivoting towards new markets and backward integration to stabilize margins.
Supriya Lifescience achieved record Q4 revenue of ₹277cr, bringing FY26 revenue to ₹828cr. Management maintained its guidance of 20% annual growth and 33-35% EBITDA margins.
Supriya Lifescience delivered strong FY26 results with Q4 revenue surging 50% YoY, driven by the anesthetic segment and European market dominance.
Supriya Lifescience delivered strong performance in Q4FY26 with 50% YoY revenue growth, driven by expansion in Europe and new product launches in Cardiovascular and ADHD segments.